Digestate

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Donnerstag, Mai 9, 2024
Mortality, FDA, Research and development, TEL, Systemic scleroderma, Nature, Capital, Publication, CMMB, Primary sclerosing cholangitis, European Patent Convention, Research, Communication, Proteomics, Digestate, MD, Doctor of Philosophy, Liver, UPMC, Administration, PSC, Disease, Therapy, Patent, Risk, Patient, Scleroderma, Diagnosis, Biomarker, Clinical trial, CCL24, UC, Pharmaceutical industry

TEL AVIV, Israel, May 09, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq:CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • (Nasdaq:CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2024, and provided a corporate update.
  • In January, 2024, Chemomab reported publication of new proteomics research in the peer-reviewed journal Cells reinforcing the clinical potential of CM-101 in primary sclerosing cholangitis.
  • Research and Development (R&D) Expenses: R&D expenses were $3.1 million for the first quarter of 2024, compared to $6.9 million for the first quarter of 2023.
  • General and Administrative (G&A) Expenses: G&A expenses were $0.9 million for the first quarter of 2024, compared to $2.2 million for the first quarter of 2023.

Bayer Introduces Iberogast™ in the U.S., Bringing Proven Plant-Based Relief to the Millions Who Experience Gut Health Issues

Retrieved on: 
Mittwoch, April 24, 2024
Research, Biotechnology, Other Health, Alternative Medicine, Health, Pharmaceutical, General Health, Other Science, Science, USD, CVS, Target, Walmart, Nature, Meal, Food, Nausea, Stomach, Digestate, Growth, Bloating, Plant, Amazon, Disease, Patient, Trust, Multimedia, Peppermint, Heartburn, Ageing

Iberogast helps reduce stomach acid, regulate stomach muscles, calm gut nerves, and support both the gut lining and microbiome.

Key Points: 
  • Iberogast helps reduce stomach acid, regulate stomach muscles, calm gut nerves, and support both the gut lining and microbiome.
  • *
    Caraway helps relax certain intestinal muscles, reduces acidity in the stomach and helps relieve occasional indigestion when combined with peppermint.
  • “With tens of millions of Americans experiencing occasional digestive health issues, this clinically proven, game-changing product will allow them to experience the power of nature and its incredible abilities to support gut health.
  • Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.

Expanding Access to Sedation-Free TNE with the EvoEndo® Endoscopy System

Retrieved on: 
Mittwoch, April 10, 2024
Surgery, Medical Devices, Medical Supplies, Parenting, Children, Hospitals, Health Technology, Health, Consumer, FDA, Physician, CMO, TNE, Risk, Hospital, Digestate, MD, Charles Palmer-Tomkinson, Extrapyramidal system, Patient, Diagnosis, Standard of care, Dentistry

EvoEndo®, Inc. (“EvoEndo”) is proud to announce it continues to expand access to sedation-free TNE (Transnasal Endoscopy), making this vital, safer alternative available to more children nationwide.

Key Points: 
  • EvoEndo®, Inc. (“EvoEndo”) is proud to announce it continues to expand access to sedation-free TNE (Transnasal Endoscopy), making this vital, safer alternative available to more children nationwide.
  • Sedation-free TNE utilizing the EvoEndo® Single-Use Endoscopy System is a minimally invasive procedure for examining the upper gastrointestinal tract.
  • It eliminates the potential complications and inconveniences associated with general anesthesia and is FDA-Cleared for use in patients five and older.
  • We are dedicated to bringing our novel technology to every state, expanding access to this alternative to all GI pediatric patients.

Power Knot Receives Orders for the LFC Biodigester from His Majesty's Prison Service

Retrieved on: 
Mittwoch, April 24, 2024
CSC, HMPS, Carbon, Digestate, Correctional Service of Canada, LFC, His Majesty's Prison Service, Lumber

After an extensive evaluation of food waste options with Power Knot UK, HMPS chose Power Knot as their premier organic waste management provider and placed orders for more than 50 units of the LFC biodigester.

Key Points: 
  • After an extensive evaluation of food waste options with Power Knot UK, HMPS chose Power Knot as their premier organic waste management provider and placed orders for more than 50 units of the LFC biodigester.
  • "Multiple orders from HMPS demonstrate that the LFC biodigester is the best in the industry," said Iain Milnes, President of Power Knot.
  • HMPS joins the Correctional Service Canada (CSC) as part of the many federal prison systems currently relying on the LFC biodigester as their food waste solution.
  • The LFC Security Package helps prevent any unauthorized person from configuring, using, or otherwise tampering with the LFC biodigester.

NUH LAUNCHES NEW DIGESTIVE CENTRE TO PUSH NEW FRONTIERS IN EARLY CANCER DETECTION AND CARE EXCELLENCE

Retrieved on: 
Dienstag, April 16, 2024
Radiation, Cade, Cancer, CAQ, Mouth, Pancreas, Tissue, AI, Colorectal cancer, Prognosis, Annual report, Stomach, Surgeon, Digestate, Artificial intelligence, Stomach cancer, Consultant, Hepatology, Radiology, National University Hospital, Computer, Incidence, Patient, Endoscopy, Diagnosis, Biomarker, Associate, Liver cancer, Division, Head, NUH, Medical imaging

SINGAPORE, April 16, 2024 /PRNewswire/ -- The National University Hospital (NUH) is embarking on a major initiative to establish the National University Centre for Digestive Health, slated for completion in the first half of 2025. With a vision to be the region's leading academic centre for digestive health, the Centre will pioneer research, innovations and clinical practices with an amplified focus to elevate the standards of early disease detection, precise diagnosis, treatment and prevention of digestive illnesses.

Key Points: 
  • Early gastrointestinal lesions, which are abnormal changes involving the tissues in the stomach area, may be indicative of cancer.
  • As such, early detection and diagnosis are crucial for better prognosis and lay a strong foundation for successful treatment and recovery.
  • The team is also developing novel biomarkers to improve the precision of early colorectal cancer detection, as well as new pancreas and liver cancer assays.
  • As we continue to expand our infrastructure and embrace technological advances, the Centre is poised to redefine digestive health for the future."

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Retrieved on: 
Dienstag, April 2, 2024
Q&A, Primary sclerosing cholangitis, Liver disease, UC, UPMC, KOL, PSC, Doctor of Philosophy, Digestate, CCL24, Clinical trial, Therapy, CMMB, Liver, University of California, Davis, FDA, TEL, Pharmaceutical industry

TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced it will host a live key opinion leader (KOL) virtual event on primary sclerosing cholangitis (PSC) on Wednesday, April 10, 2024 at 10:00 AM ET. To register, click here.

Key Points: 
  • —“Breaking New Ground: Expert Perspectives on Primary Sclerosing Cholangitis” Will Feature Clinical, Academic and Patient Advocacy Leaders Discussing PSC Disease Management and Evolving Views on Clinical Development—
    TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today announced it will host a live key opinion leader (KOL) virtual event on primary sclerosing cholangitis (PSC) on Wednesday, April 10, 2024 at 10:00 AM ET.
  • They will discuss the urgent need for new PSC treatments and emerging developments that could facilitate new drug approvals.
  • Chemomab’s co-founder, CEO & CSO Adi Mor, PhD and CMO Matt Frankel, MD, will provide an overview of the CM-101 Phase 2 PSC clinical trial that will report topline results midyear 2024.
  • CM-101 is a dual mechanism first-in-class monoclonal antibody that neutralizes CCL24, a soluble protein that is a key driver of inflammatory and fibrotic pathways central to PSC and other fibro-inflammatory diseases.

Mahana Therapeutics Acquires Cara Care to Become a Global Leader in the Digital Treatment of Chronic Conditions

Retrieved on: 
Dienstag, März 12, 2024
Software, Biotechnology, Pharmaceutical, General Health, Health, Health Technology, Technology, Apps, Applications, Partnership, Patient, Irritable bowel syndrome, Acquisition, CBT, Heartburn, Digestate, IBD, Bayer, Patient satisfaction, Cognitive behavioral therapy, Therapy, IBS, Lux Capital, FDA, Digestive, Coeliac disease, Gesellschaft mit beschränkter Haftung, Nursing

Mahana Therapeutics, a leading provider of digital chronic condition management programs, announced today that it has acquired Berlin-based HiDoc Technologies GmbH, operating as Cara Care, a leader in digital digestive healthcare.

Key Points: 
  • Mahana Therapeutics, a leading provider of digital chronic condition management programs, announced today that it has acquired Berlin-based HiDoc Technologies GmbH, operating as Cara Care, a leader in digital digestive healthcare.
  • The acquisition of Cara Care is expected to accelerate Mahana’s market entry in Europe where the reimbursement of digital programs is outpacing the United States.
  • Cara Care’s IBS prescription-based digital program is currently being prescribed, and reimbursed, to thousands of patients in Germany.
  • "The combination of Mahana and Cara Care is an incredible opportunity to bring together our complementary expertise in chronic digestive health conditions and create a one-of-a-kind global offering of digital programs across the Digestive, Hearing, Dermatology, and Women’s Health markets.

Princess Cruises Installs Innovative Food Waste Biodigesters Onboard New Flagship: Sun Princess

Retrieved on: 
Freitag, März 1, 2024
Digestate, WEP, Sun, Princess Cruises, Digestion, Sun Princess, Waste management, Power, Water, LFC, Renewable energy

The integration of Power Knot's LFC biodigesters and WEP effluent pumps on board Sun Princess marks a significant stride toward sustainable waste management practices within the cruise industry.

Key Points: 
  • The integration of Power Knot's LFC biodigesters and WEP effluent pumps on board Sun Princess marks a significant stride toward sustainable waste management practices within the cruise industry.
  • Sun Princess, Princess Cruises' newest flagship, weighing 175,500 tons and accommodating 4,300 guests, is set to make its debut in early 2024.
  • The LFC biodigester is a food waste biodigester that uses natural aerobic digestion to break down food waste into water, mitigating the need for traditional disposal methods and contributing to a substantial reduction in both cost and environmental impact.
  • "The installation of our LFC biodigesters and WEP effluent pumps on the Sun Princess exemplifies our dedication to sustainable waste management solutions.

Allied Digestive Health and Provation Sign Agreement for Enhanced Patient Care

Retrieved on: 
Donnerstag, Januar 18, 2024
Technology, Surgery, Medical Devices, Hospitals, Health Technology, Software, Managed Care, Health, Data Management, Patient, ASC, FTV, Life, OBS, Documentation, Software as a service, ADH, Nursing, Fortive, GI, Digestate, Physician

For ADH, the mission to deliver top-tier patient care while running operations efficiently is a top priority.

Key Points: 
  • For ADH, the mission to deliver top-tier patient care while running operations efficiently is a top priority.
  • ADH's decision to incorporate both Provation Apex Procedure Documentation and Patient Charting solutions demonstrates leadership in the clinical care space.
  • With Provation Apex, physicians and nurses have the power to document patient visits and procedures seamlessly, on any internet-enabled device.
  • ADH and Provation have a shared vision of the future of GI patient care through enhanced workflow automation and procedure documentation.

MiraLAX® Exposes The Gut Gap™, Proving Women are More Stressed and More Constipated than Men

Retrieved on: 
Mittwoch, Januar 17, 2024
Biotechnology, General Health, Pharmaceutical, Health, Ageing, Woman, Laughter, Multimedia, Hormone, Macrogol, Constipation, Movement, Human, Marketing, Digestate, Nursing

This high frequency of stress and constipation that American women are facing is what MiraLAX has coined “The Gut Gap™.” With 9 in 10 millennial women reporting that stress impacts their gut, MiraLAX is committed to exposing – and closing – The Gut Gap and helping women get the relief they need.

Key Points: 
  • This high frequency of stress and constipation that American women are facing is what MiraLAX has coined “The Gut Gap™.” With 9 in 10 millennial women reporting that stress impacts their gut, MiraLAX is committed to exposing – and closing – The Gut Gap and helping women get the relief they need.
  • While this stress can cause constipation in women, the inverse is also true – two in three women feel more stressed when they experience constipation.
  • Women, in part due to societal pressures and burdens, but also hormones, are particularly susceptible to stress-induced constipation.
  • For additional information and to see Abbi and Ilana take on The Gut Gap, visit TheGutGap.com.